| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 306 | 2024 | 7062 | 20.270 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 86 | 2024 | 979 | 10.590 |
Why?
|
| Sulfonamides | 97 | 2024 | 1896 | 9.560 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 70 | 2024 | 1515 | 6.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 150 | 2024 | 16258 | 5.960 |
Why?
|
| Antineoplastic Agents | 123 | 2024 | 14497 | 5.650 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 71 | 2024 | 2847 | 5.460 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 48 | 2024 | 819 | 4.950 |
Why?
|
| Apoptosis | 125 | 2023 | 7756 | 4.850 |
Why?
|
| Hematologic Neoplasms | 33 | 2024 | 1919 | 3.910 |
Why?
|
| Cytarabine | 56 | 2023 | 1993 | 3.810 |
Why?
|
| Leukemia | 30 | 2024 | 1654 | 3.710 |
Why?
|
| Protein Kinase Inhibitors | 71 | 2024 | 4884 | 3.510 |
Why?
|
| Bone Marrow | 37 | 2021 | 2374 | 3.380 |
Why?
|
| Azacitidine | 42 | 2024 | 1191 | 3.210 |
Why?
|
| Drug Resistance, Neoplasm | 74 | 2024 | 5292 | 3.140 |
Why?
|
| Leukemia, Myeloid | 25 | 2021 | 964 | 3.130 |
Why?
|
| Philadelphia Chromosome | 35 | 2024 | 822 | 3.080 |
Why?
|
| Oleanolic Acid | 25 | 2012 | 110 | 3.070 |
Why?
|
| Neoplastic Stem Cells | 23 | 2022 | 1469 | 3.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 28 | 2024 | 495 | 3.010 |
Why?
|
| Receptors, CXCR4 | 17 | 2019 | 273 | 2.870 |
Why?
|
| Humans | 592 | 2024 | 270303 | 2.750 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 33 | 2023 | 2585 | 2.670 |
Why?
|
| Myelodysplastic Syndromes | 41 | 2024 | 3063 | 2.570 |
Why?
|
| Isocitrate Dehydrogenase | 18 | 2023 | 501 | 2.480 |
Why?
|
| Dendritic Cells | 25 | 2024 | 1118 | 2.390 |
Why?
|
| Biphenyl Compounds | 15 | 2021 | 194 | 2.350 |
Why?
|
| Mutation | 97 | 2024 | 15578 | 2.230 |
Why?
|
| Prodrugs | 7 | 2021 | 220 | 2.040 |
Why?
|
| Neoplasm Proteins | 20 | 2021 | 3289 | 2.020 |
Why?
|
| Nitrophenols | 14 | 2021 | 94 | 2.010 |
Why?
|
| Aged | 226 | 2024 | 72685 | 2.000 |
Why?
|
| Myeloproliferative Disorders | 15 | 2024 | 801 | 1.990 |
Why?
|
| Tumor Microenvironment | 21 | 2024 | 2980 | 1.980 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 46 | 2024 | 6768 | 1.960 |
Why?
|
| TOR Serine-Threonine Kinases | 16 | 2018 | 1559 | 1.950 |
Why?
|
| Tumor Suppressor Protein p53 | 34 | 2024 | 3619 | 1.860 |
Why?
|
| Cell Line, Tumor | 103 | 2024 | 14851 | 1.820 |
Why?
|
| Molecular Targeted Therapy | 16 | 2024 | 2371 | 1.810 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 15 | 2024 | 111 | 1.720 |
Why?
|
| Fusion Proteins, bcr-abl | 24 | 2023 | 1126 | 1.700 |
Why?
|
| Enzyme Inhibitors | 15 | 2021 | 1937 | 1.680 |
Why?
|
| bcl-X Protein | 12 | 2023 | 199 | 1.680 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 309 | 1.670 |
Why?
|
| Middle Aged | 224 | 2024 | 89347 | 1.660 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 20 | 2023 | 284 | 1.660 |
Why?
|
| Adult | 210 | 2024 | 80561 | 1.650 |
Why?
|
| Remission Induction | 52 | 2023 | 3620 | 1.640 |
Why?
|
| Gene Expression Regulation, Leukemic | 29 | 2020 | 570 | 1.630 |
Why?
|
| Aged, 80 and over | 127 | 2024 | 30718 | 1.580 |
Why?
|
| Signal Transduction | 54 | 2024 | 12136 | 1.530 |
Why?
|
| Blast Crisis | 18 | 2022 | 581 | 1.450 |
Why?
|
| Animals | 131 | 2024 | 60962 | 1.430 |
Why?
|
| Recombinant Fusion Proteins | 10 | 2024 | 1595 | 1.390 |
Why?
|
| Imidazoles | 30 | 2024 | 1029 | 1.390 |
Why?
|
| Mitochondria | 22 | 2022 | 1306 | 1.380 |
Why?
|
| Hypoxia | 4 | 2016 | 456 | 1.360 |
Why?
|
| Male | 225 | 2024 | 127343 | 1.360 |
Why?
|
| Piperazines | 35 | 2021 | 2130 | 1.350 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 17 | 2023 | 518 | 1.340 |
Why?
|
| Flow Cytometry | 31 | 2021 | 3071 | 1.330 |
Why?
|
| Idarubicin | 17 | 2023 | 454 | 1.310 |
Why?
|
| Phenylurea Compounds | 16 | 2024 | 598 | 1.300 |
Why?
|
| Leukemia, Promyelocytic, Acute | 11 | 2021 | 439 | 1.290 |
Why?
|
| Female | 231 | 2024 | 146977 | 1.270 |
Why?
|
| Pyridines | 20 | 2022 | 1289 | 1.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 20 | 2021 | 2084 | 1.220 |
Why?
|
| Young Adult | 99 | 2023 | 22092 | 1.220 |
Why?
|
| Receptors, Cytokine | 9 | 2023 | 180 | 1.220 |
Why?
|
| Chemokine CXCL12 | 11 | 2019 | 132 | 1.210 |
Why?
|
| Mice | 103 | 2024 | 35298 | 1.210 |
Why?
|
| Mice, Inbred NOD | 22 | 2021 | 904 | 1.200 |
Why?
|
| Pyrimidines | 24 | 2021 | 3603 | 1.190 |
Why?
|
| Hematopoietic Stem Cells | 12 | 2022 | 1266 | 1.180 |
Why?
|
| Salvage Therapy | 15 | 2021 | 2095 | 1.180 |
Why?
|
| Pyridazines | 11 | 2024 | 306 | 1.150 |
Why?
|
| Oxidative Phosphorylation | 5 | 2023 | 258 | 1.140 |
Why?
|
| Nitroimidazoles | 3 | 2016 | 105 | 1.140 |
Why?
|
| Fatty Acids | 4 | 2018 | 460 | 1.130 |
Why?
|
| Glutamine | 5 | 2022 | 303 | 1.120 |
Why?
|
| Recurrence | 35 | 2024 | 4877 | 1.120 |
Why?
|
| Mice, SCID | 25 | 2021 | 1868 | 1.120 |
Why?
|
| Acute Disease | 31 | 2023 | 2472 | 1.080 |
Why?
|
| Niacinamide | 13 | 2015 | 423 | 1.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2017 | 395 | 1.070 |
Why?
|
| Phosphoramide Mustards | 2 | 2016 | 37 | 1.070 |
Why?
|
| Proteomics | 6 | 2022 | 1421 | 1.070 |
Why?
|
| Azetidines | 2 | 2024 | 91 | 1.060 |
Why?
|
| Antibodies, Bispecific | 9 | 2023 | 266 | 1.060 |
Why?
|
| Treatment Outcome | 94 | 2024 | 34144 | 1.050 |
Why?
|
| Dancing | 2 | 2022 | 22 | 1.050 |
Why?
|
| PPAR gamma | 7 | 2010 | 231 | 1.040 |
Why?
|
| U937 Cells | 19 | 2019 | 172 | 1.030 |
Why?
|
| Neoplasm, Residual | 23 | 2023 | 1716 | 1.030 |
Why?
|
| Cell Proliferation | 42 | 2021 | 7300 | 1.020 |
Why?
|
| Antigens, CD | 8 | 2023 | 1409 | 1.020 |
Why?
|
| Coculture Techniques | 13 | 2020 | 632 | 1.020 |
Why?
|
| Skin Neoplasms | 14 | 2024 | 4775 | 1.010 |
Why?
|
| Antimetabolites, Antineoplastic | 16 | 2021 | 1329 | 1.000 |
Why?
|
| Prognosis | 72 | 2024 | 22228 | 0.990 |
Why?
|
| Xenograft Model Antitumor Assays | 28 | 2024 | 3930 | 0.990 |
Why?
|
| Piperidines | 7 | 2024 | 1067 | 0.990 |
Why?
|
| Nitrogen Mustard Compounds | 3 | 2015 | 73 | 0.990 |
Why?
|
| Tumor Cells, Cultured | 37 | 2021 | 5509 | 0.980 |
Why?
|
| Apoptosis Regulatory Proteins | 9 | 2022 | 628 | 0.970 |
Why?
|
| Phosphorylation | 40 | 2019 | 4885 | 0.960 |
Why?
|
| Cell Survival | 30 | 2021 | 3061 | 0.960 |
Why?
|
| Stromal Cells | 12 | 2019 | 831 | 0.960 |
Why?
|
| Drug Delivery Systems | 6 | 2018 | 682 | 0.950 |
Why?
|
| Morpholines | 8 | 2017 | 293 | 0.950 |
Why?
|
| Heterocyclic Compounds | 5 | 2020 | 121 | 0.940 |
Why?
|
| Vidarabine | 12 | 2022 | 1362 | 0.930 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 10 | 2022 | 472 | 0.930 |
Why?
|
| Vincristine | 24 | 2022 | 1532 | 0.920 |
Why?
|
| Disease-Free Survival | 48 | 2023 | 10092 | 0.890 |
Why?
|
| Cyclophosphamide | 26 | 2022 | 3143 | 0.890 |
Why?
|
| Cell Differentiation | 21 | 2024 | 4169 | 0.890 |
Why?
|
| Transplantation Conditioning | 7 | 2021 | 2301 | 0.880 |
Why?
|
| Adipocytes | 5 | 2018 | 312 | 0.880 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 873 | 0.880 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 7 | 2023 | 215 | 0.870 |
Why?
|
| Bone Marrow Cells | 14 | 2021 | 928 | 0.870 |
Why?
|
| Dexamethasone | 24 | 2022 | 1471 | 0.860 |
Why?
|
| Oncogene Proteins, Fusion | 11 | 2020 | 779 | 0.860 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2023 | 1069 | 0.860 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 6 | 2021 | 204 | 0.840 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2022 | 759 | 0.820 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 10254 | 0.820 |
Why?
|
| HL-60 Cells | 19 | 2021 | 306 | 0.810 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 6 | 2020 | 524 | 0.810 |
Why?
|
| Transplantation, Homologous | 13 | 2023 | 2942 | 0.810 |
Why?
|
| Proto-Oncogene Proteins | 16 | 2021 | 2547 | 0.800 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2019 | 267 | 0.800 |
Why?
|
| Drug Synergism | 25 | 2019 | 1336 | 0.790 |
Why?
|
| Benzamides | 19 | 2017 | 1873 | 0.790 |
Why?
|
| Indazoles | 3 | 2013 | 302 | 0.780 |
Why?
|
| Stem Cell Niche | 3 | 2017 | 91 | 0.780 |
Why?
|
| Leukemia, Experimental | 3 | 2016 | 78 | 0.780 |
Why?
|
| Adolescent | 78 | 2024 | 32284 | 0.770 |
Why?
|
| Aniline Compounds | 6 | 2024 | 195 | 0.770 |
Why?
|
| Survival Analysis | 40 | 2021 | 9322 | 0.770 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2021 | 6269 | 0.750 |
Why?
|
| Immune Evasion | 1 | 2021 | 77 | 0.750 |
Why?
|
| Imatinib Mesylate | 15 | 2019 | 1687 | 0.750 |
Why?
|
| Dasatinib | 11 | 2023 | 877 | 0.740 |
Why?
|
| Benzeneacetamides | 2 | 2019 | 28 | 0.740 |
Why?
|
| Transcription Factors | 17 | 2023 | 5364 | 0.740 |
Why?
|
| Nuclear Proteins | 15 | 2023 | 3385 | 0.730 |
Why?
|
| Thiadiazoles | 2 | 2019 | 47 | 0.730 |
Why?
|
| Glutaminase | 2 | 2019 | 49 | 0.730 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 131 | 0.720 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 8 | 2022 | 383 | 0.710 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 203 | 0.710 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 6 | 2022 | 450 | 0.700 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2023 | 2425 | 0.700 |
Why?
|
| Drug Administration Schedule | 19 | 2021 | 3518 | 0.700 |
Why?
|
| Myelitis, Transverse | 1 | 2019 | 13 | 0.690 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.680 |
Why?
|
| Doxorubicin | 28 | 2022 | 3059 | 0.680 |
Why?
|
| B-Lymphocytes | 11 | 2023 | 1347 | 0.670 |
Why?
|
| Gene Rearrangement | 9 | 2023 | 797 | 0.670 |
Why?
|
| Retrospective Studies | 68 | 2024 | 39457 | 0.660 |
Why?
|
| MAP Kinase Signaling System | 10 | 2022 | 885 | 0.660 |
Why?
|
| Optic Neuritis | 1 | 2019 | 39 | 0.650 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 13 | 0.650 |
Why?
|
| Pyrroles | 4 | 2022 | 594 | 0.650 |
Why?
|
| Induction Chemotherapy | 15 | 2023 | 666 | 0.640 |
Why?
|
| Survival Rate | 40 | 2024 | 12429 | 0.640 |
Why?
|
| Blotting, Western | 21 | 2015 | 3596 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2015 | 45 | 0.620 |
Why?
|
| Neoplasms | 10 | 2023 | 15695 | 0.620 |
Why?
|
| Receptors, Interleukin-3 | 2 | 2014 | 26 | 0.610 |
Why?
|
| Arabinonucleosides | 8 | 2021 | 447 | 0.610 |
Why?
|
| DNA Modification Methylases | 2 | 2022 | 173 | 0.610 |
Why?
|
| Indoles | 5 | 2019 | 1021 | 0.590 |
Why?
|
| Histone Deacetylase Inhibitors | 6 | 2023 | 620 | 0.590 |
Why?
|
| Cell Cycle | 18 | 2018 | 2115 | 0.580 |
Why?
|
| Tumor Hypoxia | 1 | 2017 | 24 | 0.580 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2013 | 43 | 0.560 |
Why?
|
| Sulfides | 1 | 2016 | 48 | 0.560 |
Why?
|
| Genomics | 7 | 2022 | 2818 | 0.560 |
Why?
|
| Histone Demethylases | 1 | 2018 | 147 | 0.560 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2019 | 5028 | 0.560 |
Why?
|
| Graft vs Host Disease | 11 | 2024 | 2718 | 0.560 |
Why?
|
| Cladribine | 7 | 2023 | 252 | 0.540 |
Why?
|
| Propensity Score | 7 | 2022 | 784 | 0.540 |
Why?
|
| Benzoxazoles | 1 | 2016 | 41 | 0.540 |
Why?
|
| Genes, bcl-2 | 5 | 2015 | 168 | 0.540 |
Why?
|
| DNA Methylation | 11 | 2021 | 2733 | 0.540 |
Why?
|
| Energy Metabolism | 5 | 2019 | 1008 | 0.540 |
Why?
|
| Amino Acids | 1 | 2019 | 758 | 0.540 |
Why?
|
| Thiazolidines | 1 | 2015 | 15 | 0.530 |
Why?
|
| Busulfan | 3 | 2020 | 778 | 0.530 |
Why?
|
| Aminopyridines | 5 | 2022 | 219 | 0.530 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 28 | 0.530 |
Why?
|
| Stem Cell Transplantation | 9 | 2023 | 1384 | 0.530 |
Why?
|
| Models, Biological | 7 | 2020 | 3252 | 0.520 |
Why?
|
| Asparaginase | 8 | 2024 | 186 | 0.520 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2024 | 1313 | 0.520 |
Why?
|
| Benzimidazoles | 5 | 2021 | 438 | 0.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 3362 | 0.510 |
Why?
|
| Carnitine | 1 | 2015 | 93 | 0.500 |
Why?
|
| Fetal Blood | 4 | 2021 | 479 | 0.500 |
Why?
|
| Methyltransferases | 3 | 2022 | 149 | 0.490 |
Why?
|
| Cell Cycle Proteins | 11 | 2023 | 2099 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 7 | 2022 | 4442 | 0.490 |
Why?
|
| Benzylamines | 5 | 2020 | 103 | 0.490 |
Why?
|
| T-Lymphocytes | 15 | 2024 | 3955 | 0.490 |
Why?
|
| Histone-Lysine N-Methyltransferase | 5 | 2021 | 463 | 0.490 |
Why?
|
| Peptides, Cyclic | 1 | 2015 | 138 | 0.480 |
Why?
|
| Protein-Tyrosine Kinases | 10 | 2021 | 1787 | 0.480 |
Why?
|
| Pyrazoles | 6 | 2021 | 1517 | 0.470 |
Why?
|
| DNA-Binding Proteins | 10 | 2023 | 4907 | 0.470 |
Why?
|
| Follow-Up Studies | 31 | 2021 | 15176 | 0.470 |
Why?
|
| Antigens, CD34 | 12 | 2019 | 591 | 0.460 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2015 | 595 | 0.460 |
Why?
|
| Unrelated Donors | 3 | 2024 | 322 | 0.450 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2020 | 306 | 0.440 |
Why?
|
| Febrile Neutropenia | 3 | 2024 | 71 | 0.440 |
Why?
|
| Tandem Repeat Sequences | 7 | 2020 | 202 | 0.440 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 3 | 2024 | 88 | 0.440 |
Why?
|
| Cell Movement | 7 | 2019 | 2498 | 0.440 |
Why?
|
| Triazines | 4 | 2022 | 117 | 0.440 |
Why?
|
| para-Aminobenzoates | 3 | 2022 | 10 | 0.430 |
Why?
|
| Caspases | 11 | 2011 | 685 | 0.430 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 151 | 0.430 |
Why?
|
| Benzenesulfonates | 6 | 2012 | 196 | 0.430 |
Why?
|
| Primary Myelofibrosis | 4 | 2024 | 878 | 0.430 |
Why?
|
| Daunorubicin | 5 | 2021 | 304 | 0.430 |
Why?
|
| Purines | 2 | 2023 | 275 | 0.420 |
Why?
|
| Immunoconjugates | 3 | 2024 | 302 | 0.420 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1049 | 0.410 |
Why?
|
| Pyrrolidines | 3 | 2022 | 113 | 0.410 |
Why?
|
| Gossypol | 3 | 2017 | 28 | 0.400 |
Why?
|
| Alleles | 7 | 2020 | 2479 | 0.400 |
Why?
|
| Benzoates | 2 | 2019 | 133 | 0.390 |
Why?
|
| Janus Kinase 2 | 5 | 2023 | 686 | 0.390 |
Why?
|
| Membrane Microdomains | 1 | 2011 | 84 | 0.390 |
Why?
|
| Sirolimus | 5 | 2022 | 834 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1377 | 0.380 |
Why?
|
| Lymphoma, Mantle-Cell | 6 | 2017 | 736 | 0.380 |
Why?
|
| Histocompatibility Testing | 3 | 2024 | 465 | 0.370 |
Why?
|
| Cell Division | 15 | 2008 | 2554 | 0.370 |
Why?
|
| Cell Communication | 4 | 2009 | 506 | 0.370 |
Why?
|
| Adenine Nucleotides | 5 | 2017 | 360 | 0.370 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 7 | 2017 | 598 | 0.370 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2010 | 8 | 0.370 |
Why?
|
| RNA, Messenger | 16 | 2016 | 6222 | 0.370 |
Why?
|
| Receptors, Immunologic | 3 | 2023 | 317 | 0.360 |
Why?
|
| Lymphoma, B-Cell | 4 | 2023 | 917 | 0.360 |
Why?
|
| Enzyme Activation | 15 | 2015 | 1798 | 0.360 |
Why?
|
| Tretinoin | 11 | 2021 | 637 | 0.360 |
Why?
|
| Clonal Evolution | 3 | 2020 | 252 | 0.360 |
Why?
|
| Cells, Cultured | 13 | 2021 | 5667 | 0.360 |
Why?
|
| Autophagy | 4 | 2023 | 931 | 0.350 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 387 | 0.350 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 3 | 2021 | 120 | 0.350 |
Why?
|
| bcl-2-Associated X Protein | 9 | 2022 | 371 | 0.350 |
Why?
|
| src-Family Kinases | 2 | 2014 | 480 | 0.350 |
Why?
|
| Gene Expression Profiling | 14 | 2021 | 5239 | 0.350 |
Why?
|
| Carrier Proteins | 7 | 2017 | 2054 | 0.350 |
Why?
|
| NAD+ Nucleosidase | 2 | 2000 | 17 | 0.350 |
Why?
|
| Maximum Tolerated Dose | 10 | 2021 | 1314 | 0.340 |
Why?
|
| Biomarkers, Tumor | 16 | 2021 | 10623 | 0.340 |
Why?
|
| Chromosome Aberrations | 9 | 2022 | 1978 | 0.340 |
Why?
|
| Triazoles | 4 | 2021 | 630 | 0.340 |
Why?
|
| Methotrexate | 6 | 2022 | 1022 | 0.340 |
Why?
|
| Transplantation, Haploidentical | 3 | 2019 | 155 | 0.330 |
Why?
|
| Membrane Proteins | 7 | 2014 | 2914 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 3665 | 0.330 |
Why?
|
| Gene Expression | 12 | 2016 | 3596 | 0.330 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 1431 | 0.330 |
Why?
|
| Nitriles | 6 | 2021 | 935 | 0.330 |
Why?
|
| Disease Management | 4 | 2022 | 1102 | 0.320 |
Why?
|
| Pyrazines | 4 | 2024 | 508 | 0.320 |
Why?
|
| Administration, Oral | 7 | 2019 | 1583 | 0.320 |
Why?
|
| Protein Binding | 8 | 2021 | 3480 | 0.320 |
Why?
|
| Antigens, Differentiation | 2 | 2000 | 247 | 0.310 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 5114 | 0.310 |
Why?
|
| Allografts | 6 | 2022 | 680 | 0.310 |
Why?
|
| Pneumonia | 3 | 2023 | 759 | 0.310 |
Why?
|
| Lactic Acid | 3 | 2019 | 310 | 0.310 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2023 | 1706 | 0.310 |
Why?
|
| Membrane Glycoproteins | 8 | 2021 | 1098 | 0.310 |
Why?
|
| Genes, ras | 4 | 2022 | 672 | 0.310 |
Why?
|
| ras Proteins | 4 | 2022 | 783 | 0.310 |
Why?
|
| Gene Frequency | 4 | 2021 | 1181 | 0.310 |
Why?
|
| Translocation, Genetic | 8 | 2023 | 1269 | 0.310 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2019 | 409 | 0.300 |
Why?
|
| Stem Cells | 5 | 2022 | 1244 | 0.300 |
Why?
|
| Immunophenotyping | 7 | 2021 | 1700 | 0.300 |
Why?
|
| Benzothiazoles | 3 | 2024 | 103 | 0.300 |
Why?
|
| Dioxygenases | 3 | 2023 | 165 | 0.300 |
Why?
|
| Consolidation Chemotherapy | 5 | 2020 | 156 | 0.300 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1143 | 0.300 |
Why?
|
| Burkitt Lymphoma | 4 | 2023 | 345 | 0.290 |
Why?
|
| Adenylate Kinase | 2 | 2018 | 35 | 0.290 |
Why?
|
| Peptide Fragments | 5 | 2017 | 1294 | 0.290 |
Why?
|
| Cytokines | 5 | 2022 | 2869 | 0.290 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 546 | 0.290 |
Why?
|
| Annexin A1 | 1 | 2007 | 40 | 0.290 |
Why?
|
| NF-kappa B | 6 | 2021 | 1585 | 0.290 |
Why?
|
| Activating Transcription Factor 4 | 2 | 2018 | 78 | 0.290 |
Why?
|
| Cell Line | 12 | 2023 | 5128 | 0.290 |
Why?
|
| Transplantation, Heterologous | 6 | 2014 | 1091 | 0.290 |
Why?
|
| Cell Hypoxia | 3 | 2012 | 335 | 0.290 |
Why?
|
| Glycolysis | 4 | 2021 | 530 | 0.290 |
Why?
|
| Oxidation-Reduction | 5 | 2018 | 729 | 0.280 |
Why?
|
| Cohort Studies | 14 | 2024 | 9471 | 0.280 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 231 | 0.280 |
Why?
|
| Neoplasm Transplantation | 7 | 2019 | 1533 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 4641 | 0.280 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 43 | 0.280 |
Why?
|
| Protein Kinases | 3 | 2008 | 888 | 0.280 |
Why?
|
| raf Kinases | 2 | 2007 | 81 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2019 | 2395 | 0.280 |
Why?
|
| Anemia | 3 | 2020 | 728 | 0.280 |
Why?
|
| Genes, p53 | 5 | 2017 | 1122 | 0.280 |
Why?
|
| Reactive Oxygen Species | 13 | 2021 | 1005 | 0.270 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 2 | 2024 | 60 | 0.270 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2020 | 343 | 0.270 |
Why?
|
| Prospective Studies | 20 | 2022 | 13265 | 0.270 |
Why?
|
| Janus Kinases | 4 | 2023 | 177 | 0.270 |
Why?
|
| Cell Death | 4 | 2018 | 675 | 0.270 |
Why?
|
| Protein Array Analysis | 4 | 2019 | 504 | 0.270 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 3 | 2021 | 271 | 0.270 |
Why?
|
| Clinical Trials as Topic | 8 | 2022 | 3835 | 0.270 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 7417 | 0.270 |
Why?
|
| Proteins | 5 | 2021 | 1986 | 0.270 |
Why?
|
| Interferon-alpha | 4 | 2022 | 904 | 0.270 |
Why?
|
| Karyotype | 6 | 2024 | 236 | 0.260 |
Why?
|
| Transcriptome | 10 | 2023 | 1952 | 0.260 |
Why?
|
| Antifungal Agents | 4 | 2021 | 854 | 0.260 |
Why?
|
| Prostaglandin D2 | 2 | 2004 | 28 | 0.260 |
Why?
|
| Heterografts | 6 | 2020 | 749 | 0.260 |
Why?
|
| Age Factors | 14 | 2021 | 5489 | 0.260 |
Why?
|
| Biomimetics | 3 | 2017 | 35 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 9064 | 0.260 |
Why?
|
| PAX5 Transcription Factor | 3 | 2022 | 45 | 0.260 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2019 | 164 | 0.250 |
Why?
|
| Single-Cell Analysis | 5 | 2021 | 525 | 0.250 |
Why?
|
| Quinolines | 2 | 2021 | 396 | 0.250 |
Why?
|
| Mycoses | 2 | 2021 | 386 | 0.250 |
Why?
|
| Protein Phosphatase 2 | 4 | 2014 | 88 | 0.250 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 86 | 0.240 |
Why?
|
| Caveolin 1 | 1 | 2006 | 207 | 0.240 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2017 | 195 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2022 | 231 | 0.240 |
Why?
|
| Oxadiazoles | 2 | 2021 | 60 | 0.240 |
Why?
|
| Single-Domain Antibodies | 1 | 2024 | 15 | 0.240 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2017 | 472 | 0.240 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 5 | 2011 | 72 | 0.240 |
Why?
|
| Up-Regulation | 8 | 2023 | 2480 | 0.240 |
Why?
|
| Repressor Proteins | 5 | 2023 | 1699 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 10 | 2022 | 2340 | 0.230 |
Why?
|
| Uridine | 1 | 2024 | 61 | 0.230 |
Why?
|
| Myeloid Progenitor Cells | 3 | 2021 | 47 | 0.230 |
Why?
|
| Chromosome Inversion | 2 | 2023 | 183 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1701 | 0.230 |
Why?
|
| Lymphoma | 4 | 2016 | 1490 | 0.230 |
Why?
|
| Risk Factors | 17 | 2021 | 18226 | 0.230 |
Why?
|
| Receptors, Cell Surface | 4 | 2023 | 877 | 0.220 |
Why?
|
| Patient Safety | 3 | 2018 | 675 | 0.220 |
Why?
|
| Glycine | 3 | 2021 | 305 | 0.220 |
Why?
|
| Anemia, Refractory | 1 | 2003 | 39 | 0.220 |
Why?
|
| Isoflavones | 1 | 2023 | 74 | 0.220 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 572 | 0.220 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 717 | 0.220 |
Why?
|
| Hypoglycemic Agents | 4 | 2012 | 607 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 5105 | 0.220 |
Why?
|
| Mercaptopurine | 3 | 2021 | 130 | 0.220 |
Why?
|
| Leukemia, B-Cell | 2 | 2021 | 114 | 0.220 |
Why?
|
| Arsenicals | 2 | 2021 | 201 | 0.220 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 679 | 0.220 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2023 | 187 | 0.220 |
Why?
|
| Thalidomide | 3 | 2019 | 577 | 0.210 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2023 | 44 | 0.210 |
Why?
|
| Asparagine | 2 | 2019 | 39 | 0.210 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 3 | 2016 | 125 | 0.210 |
Why?
|
| Tumor Burden | 5 | 2021 | 2018 | 0.210 |
Why?
|
| Mast Cells | 1 | 2024 | 230 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 5 | 2017 | 1138 | 0.210 |
Why?
|
| Child | 18 | 2024 | 30149 | 0.210 |
Why?
|
| Nucleosides | 1 | 2022 | 61 | 0.210 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 98 | 0.210 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2023 | 107 | 0.210 |
Why?
|
| Biomarkers | 8 | 2023 | 5162 | 0.210 |
Why?
|
| Gene Silencing | 3 | 2018 | 838 | 0.210 |
Why?
|
| Cellular Microenvironment | 2 | 2012 | 41 | 0.210 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2021 | 163 | 0.210 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2022 | 28 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2002 | 111 | 0.210 |
Why?
|
| Leukemia, Monocytic, Acute | 2 | 2017 | 31 | 0.210 |
Why?
|
| GATA3 Transcription Factor | 2 | 2020 | 147 | 0.210 |
Why?
|
| Bcl-2-Like Protein 11 | 5 | 2016 | 69 | 0.210 |
Why?
|
| Diphenylamine | 2 | 2012 | 15 | 0.210 |
Why?
|
| THP-1 Cells | 2 | 2019 | 55 | 0.200 |
Why?
|
| Biomimetic Materials | 1 | 2022 | 41 | 0.200 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 88 | 0.200 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1890 | 0.200 |
Why?
|
| B-Cell Activating Factor | 1 | 2021 | 25 | 0.200 |
Why?
|
| Drug Combinations | 1 | 2024 | 635 | 0.200 |
Why?
|
| Thrombocythemia, Essential | 2 | 2017 | 163 | 0.200 |
Why?
|
| Mice, Knockout | 7 | 2021 | 5794 | 0.200 |
Why?
|
| Interferon-gamma | 2 | 2024 | 1162 | 0.200 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 1149 | 0.200 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2021 | 46 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 675 | 0.200 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 2347 | 0.200 |
Why?
|
| Cysteine | 2 | 2019 | 214 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 474 | 0.200 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 4230 | 0.190 |
Why?
|
| Ribonucleoproteins | 1 | 2021 | 122 | 0.190 |
Why?
|
| Cellular Senescence | 1 | 2023 | 386 | 0.190 |
Why?
|
| Receptors, Notch | 2 | 2019 | 385 | 0.190 |
Why?
|
| Polycythemia Vera | 2 | 2017 | 240 | 0.190 |
Why?
|
| Azoles | 1 | 2021 | 48 | 0.190 |
Why?
|
| Mitochondrial Dynamics | 1 | 2021 | 69 | 0.190 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2021 | 31 | 0.190 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 61 | 0.190 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2020 | 31 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 99 | 0.190 |
Why?
|
| Membrane Potentials | 5 | 2005 | 435 | 0.190 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2012 | 131 | 0.190 |
Why?
|
| Jurkat Cells | 3 | 2006 | 315 | 0.190 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 164 | 0.190 |
Why?
|
| Pyruvic Acid | 2 | 2019 | 134 | 0.190 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2020 | 37 | 0.180 |
Why?
|
| Peptides | 1 | 2006 | 1503 | 0.180 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.180 |
Why?
|
| Sarcoma, Myeloid | 1 | 2021 | 93 | 0.180 |
Why?
|
| Histones | 5 | 2019 | 1492 | 0.180 |
Why?
|
| Drug Evaluation | 1 | 2020 | 427 | 0.180 |
Why?
|
| SEER Program | 1 | 2024 | 1012 | 0.180 |
Why?
|
| Caspase 8 | 5 | 2015 | 148 | 0.180 |
Why?
|
| Phosphoproteins | 3 | 2015 | 1177 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 127 | 0.180 |
Why?
|
| Child, Preschool | 10 | 2021 | 16762 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 2730 | 0.180 |
Why?
|
| MicroRNAs | 5 | 2014 | 2954 | 0.180 |
Why?
|
| RNA, Small Interfering | 6 | 2017 | 2221 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 349 | 0.180 |
Why?
|
| Aminoglycosides | 3 | 2016 | 224 | 0.180 |
Why?
|
| ADP-ribosyl Cyclase 1 | 5 | 2019 | 141 | 0.180 |
Why?
|
| Phenotype | 6 | 2019 | 6392 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 9002 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2020 | 81 | 0.180 |
Why?
|
| Oxygen | 2 | 2019 | 778 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1232 | 0.180 |
Why?
|
| Acetyl Coenzyme A | 1 | 2019 | 23 | 0.180 |
Why?
|
| Protein Isoforms | 4 | 2016 | 849 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 608 | 0.180 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 4067 | 0.180 |
Why?
|
| Glucose | 3 | 2017 | 1267 | 0.180 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 638 | 0.170 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 931 | 0.170 |
Why?
|
| Autoimmunity | 1 | 2021 | 275 | 0.170 |
Why?
|
| Multivariate Analysis | 7 | 2021 | 4384 | 0.170 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2021 | 188 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 1168 | 0.170 |
Why?
|
| Retreatment | 5 | 2020 | 452 | 0.170 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 36 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2021 | 188 | 0.170 |
Why?
|
| Epigenomics | 2 | 2021 | 269 | 0.170 |
Why?
|
| Capillary Leak Syndrome | 1 | 2019 | 14 | 0.170 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2019 | 23 | 0.170 |
Why?
|
| Pteridines | 1 | 2019 | 34 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2019 | 69 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 592 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 717 | 0.170 |
Why?
|
| Bortezomib | 3 | 2017 | 549 | 0.170 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 45 | 0.170 |
Why?
|
| Point Mutation | 3 | 2019 | 774 | 0.170 |
Why?
|
| Antigens, CD19 | 4 | 2023 | 586 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 1057 | 0.170 |
Why?
|
| Immunologic Factors | 3 | 2017 | 667 | 0.170 |
Why?
|
| Cell Culture Techniques | 2 | 2019 | 595 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2013 | 734 | 0.160 |
Why?
|
| Central Nervous System | 1 | 2021 | 449 | 0.160 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 93 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 319 | 0.160 |
Why?
|
| Risk | 2 | 2020 | 1997 | 0.160 |
Why?
|
| Receptors, Retinoic Acid | 5 | 2007 | 368 | 0.160 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2019 | 61 | 0.160 |
Why?
|
| Methylation | 2 | 2017 | 599 | 0.160 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 201 | 0.160 |
Why?
|
| Multienzyme Complexes | 1 | 2000 | 222 | 0.160 |
Why?
|
| Hematopoiesis | 3 | 2009 | 565 | 0.160 |
Why?
|
| Leukemic Infiltration | 1 | 2018 | 73 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2022 | 7156 | 0.160 |
Why?
|
| Patient Dropouts | 1 | 2019 | 91 | 0.160 |
Why?
|
| Electron Transport | 2 | 2016 | 83 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2020 | 2837 | 0.160 |
Why?
|
| Sepsis | 1 | 2024 | 667 | 0.160 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 964 | 0.160 |
Why?
|
| Interferon Inducers | 1 | 2017 | 10 | 0.150 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 51 | 0.150 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 54 | 0.150 |
Why?
|
| Acetylation | 4 | 2019 | 521 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 28 | 0.150 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 115 | 0.150 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 97 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 486 | 0.150 |
Why?
|
| Ceramides | 2 | 2008 | 95 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 214 | 0.150 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2017 | 32 | 0.150 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2019 | 214 | 0.150 |
Why?
|
| Multipotent Stem Cells | 1 | 2017 | 50 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2007 | 567 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2006 | 656 | 0.150 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2017 | 44 | 0.150 |
Why?
|
| Triterpenes | 3 | 2008 | 65 | 0.150 |
Why?
|
| Base Sequence | 7 | 2016 | 4929 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 342 | 0.150 |
Why?
|
| Chemotaxis | 2 | 2008 | 144 | 0.150 |
Why?
|
| DNA Damage | 4 | 2024 | 1986 | 0.150 |
Why?
|
| Acrylates | 1 | 2017 | 31 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 261 | 0.150 |
Why?
|
| Microscopy, Confocal | 3 | 2019 | 677 | 0.150 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 1430 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 604 | 0.150 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2017 | 512 | 0.150 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2019 | 335 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 1030 | 0.150 |
Why?
|
| HLA Antigens | 2 | 2024 | 566 | 0.150 |
Why?
|
| Glutamate Dehydrogenase | 1 | 2016 | 15 | 0.150 |
Why?
|
| Hydroxamic Acids | 2 | 2012 | 444 | 0.140 |
Why?
|
| Down-Regulation | 7 | 2013 | 2112 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 1607 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 78 | 0.140 |
Why?
|
| Hydrazines | 1 | 2019 | 211 | 0.140 |
Why?
|
| Leukemia, Prolymphocytic | 2 | 2007 | 53 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 87 | 0.140 |
Why?
|
| Leukemia, T-Cell | 2 | 2007 | 88 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 390 | 0.140 |
Why?
|
| Glutarates | 1 | 2016 | 44 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2017 | 316 | 0.140 |
Why?
|
| Biguanides | 1 | 2016 | 11 | 0.140 |
Why?
|
| Trans-Activators | 2 | 2022 | 1624 | 0.140 |
Why?
|
| Pyridones | 4 | 2022 | 366 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1375 | 0.140 |
Why?
|
| Single-Chain Antibodies | 1 | 2017 | 64 | 0.140 |
Why?
|
| Luciferases | 3 | 2016 | 454 | 0.140 |
Why?
|
| RNA Interference | 3 | 2019 | 1411 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Neutropenia | 3 | 2019 | 988 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 6 | 2015 | 2402 | 0.140 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 119 | 0.140 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 87 | 0.140 |
Why?
|
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2015 | 3 | 0.140 |
Why?
|
| Proteome | 2 | 2017 | 577 | 0.140 |
Why?
|
| Pyrimidinones | 4 | 2022 | 320 | 0.140 |
Why?
|
| Hyperbilirubinemia | 1 | 2016 | 77 | 0.140 |
Why?
|
| Protein Kinase C | 2 | 2011 | 397 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 53 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 223 | 0.130 |
Why?
|
| Exanthema | 2 | 2019 | 213 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 2 | 2019 | 190 | 0.130 |
Why?
|
| Alternative Splicing | 2 | 2016 | 595 | 0.130 |
Why?
|
| Arginine | 1 | 2019 | 518 | 0.130 |
Why?
|
| Receptors, Erythropoietin | 1 | 2016 | 70 | 0.130 |
Why?
|
| Gene Order | 1 | 2016 | 111 | 0.130 |
Why?
|
| Depsipeptides | 2 | 2007 | 78 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2008 | 307 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 428 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 1459 | 0.130 |
Why?
|
| Hyperglycemia | 2 | 2012 | 338 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 225 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 2616 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2017 | 292 | 0.130 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2015 | 44 | 0.130 |
Why?
|
| Metabolomics | 1 | 2019 | 484 | 0.130 |
Why?
|
| Patient Selection | 2 | 2021 | 2114 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 1183 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 298 | 0.130 |
Why?
|
| Naphthoquinones | 1 | 2015 | 19 | 0.130 |
Why?
|
| Lactones | 1 | 2016 | 95 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 224 | 0.130 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2015 | 27 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 885 | 0.130 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 369 | 0.130 |
Why?
|
| Dimerization | 2 | 2006 | 311 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 1574 | 0.130 |
Why?
|
| Caspase 3 | 5 | 2015 | 480 | 0.130 |
Why?
|
| Stomatitis | 1 | 2016 | 187 | 0.130 |
Why?
|
| Carbonic Anhydrases | 1 | 2015 | 43 | 0.130 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2015 | 37 | 0.130 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 217 | 0.130 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 2 | 2012 | 46 | 0.130 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 3 | 2011 | 119 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 11816 | 0.130 |
Why?
|
| Incidence | 6 | 2024 | 5886 | 0.130 |
Why?
|
| Esophagitis | 1 | 2016 | 204 | 0.130 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 384 | 0.120 |
Why?
|
| Infant | 8 | 2022 | 13785 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 446 | 0.120 |
Why?
|
| Immunohistochemistry | 7 | 2019 | 7702 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 1293 | 0.120 |
Why?
|
| Stem Cell Factor | 1 | 2015 | 89 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2015 | 118 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 3 | 2015 | 771 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2017 | 491 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2021 | 199 | 0.120 |
Why?
|
| Glutamic Acid | 1 | 2016 | 319 | 0.120 |
Why?
|
| Mice, Nude | 5 | 2017 | 4343 | 0.120 |
Why?
|
| Enterocolitis | 1 | 2015 | 47 | 0.120 |
Why?
|
| Phagocytosis | 2 | 2007 | 274 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 291 | 0.120 |
Why?
|
| Immunoblotting | 2 | 2014 | 898 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 459 | 0.120 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2014 | 7 | 0.120 |
Why?
|
| DNA | 1 | 2022 | 2741 | 0.120 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 11 | 0.120 |
Why?
|
| eIF-2 Kinase | 1 | 2015 | 164 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2023 | 2258 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 747 | 0.120 |
Why?
|
| Osteonectin | 1 | 2014 | 55 | 0.120 |
Why?
|
| Integrin alpha4beta1 | 1 | 2014 | 45 | 0.120 |
Why?
|
| Fluorometry | 1 | 2014 | 34 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2008 | 232 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 336 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 1503 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 5 | 2020 | 2506 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1007 | 0.110 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 185 | 0.110 |
Why?
|
| Retinoids | 2 | 2006 | 171 | 0.110 |
Why?
|
| Chromones | 3 | 2013 | 120 | 0.110 |
Why?
|
| Pruritus | 1 | 2014 | 88 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 123 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 833 | 0.110 |
Why?
|
| Insulin | 4 | 2012 | 1473 | 0.110 |
Why?
|
| Necrosis | 1 | 2015 | 598 | 0.110 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 2311 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2015 | 431 | 0.110 |
Why?
|
| Time Factors | 10 | 2019 | 13246 | 0.110 |
Why?
|
| Protein Kinase C-alpha | 3 | 2014 | 66 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 2235 | 0.110 |
Why?
|
| Phenanthrenes | 2 | 2011 | 42 | 0.110 |
Why?
|
| Cyclin D1 | 4 | 2012 | 582 | 0.110 |
Why?
|
| Adenine | 3 | 2021 | 651 | 0.110 |
Why?
|
| Ligands | 4 | 2018 | 1008 | 0.110 |
Why?
|
| Protein Conformation | 3 | 2021 | 1271 | 0.110 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 2 | 2020 | 72 | 0.110 |
Why?
|
| Retinoic Acid Receptor alpha | 2 | 2020 | 95 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 337 | 0.110 |
Why?
|
| Diterpenes | 2 | 2011 | 111 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 1558 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 696 | 0.110 |
Why?
|
| DNA Repair | 2 | 2024 | 1905 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 5025 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 684 | 0.110 |
Why?
|
| Everolimus | 3 | 2017 | 419 | 0.100 |
Why?
|
| Thiazolidinediones | 3 | 2012 | 152 | 0.100 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2012 | 68 | 0.100 |
Why?
|
| Glutathione | 3 | 2019 | 369 | 0.100 |
Why?
|
| Bacteria | 1 | 2017 | 624 | 0.100 |
Why?
|
| Transplantation, Heterotopic | 1 | 2012 | 42 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2006 | 1876 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 3 | 2012 | 83 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 509 | 0.100 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2012 | 41 | 0.100 |
Why?
|
| fas Receptor | 3 | 2006 | 193 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 774 | 0.100 |
Why?
|
| Boronic Acids | 2 | 2010 | 364 | 0.100 |
Why?
|
| Maintenance Chemotherapy | 3 | 2021 | 221 | 0.100 |
Why?
|
| Breast Neoplasms | 5 | 2013 | 16050 | 0.100 |
Why?
|
| Growth Inhibitors | 3 | 2010 | 154 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 999 | 0.100 |
Why?
|
| Feasibility Studies | 4 | 2022 | 2353 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 204 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 5706 | 0.100 |
Why?
|
| Hemorrhage | 3 | 2023 | 767 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2012 | 248 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 954 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 290 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 4 | 2010 | 5228 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2006 | 1096 | 0.090 |
Why?
|
| Coumarins | 1 | 2010 | 34 | 0.090 |
Why?
|
| Bacteremia | 1 | 2017 | 693 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 181 | 0.090 |
Why?
|
| Transcription, Genetic | 4 | 2007 | 3148 | 0.090 |
Why?
|
| Nitric Oxide | 3 | 2010 | 658 | 0.090 |
Why?
|
| Adenosine Triphosphate | 3 | 2022 | 578 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 1094 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 4052 | 0.090 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2007 | 36 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2022 | 212 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2352 | 0.090 |
Why?
|
| Interferon-beta | 1 | 2010 | 107 | 0.090 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2009 | 78 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2024 | 2316 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2020 | 6231 | 0.090 |
Why?
|
| Cell Lineage | 3 | 2021 | 700 | 0.090 |
Why?
|
| Genes, abl | 3 | 2019 | 115 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2020 | 1432 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2011 | 231 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 7157 | 0.090 |
Why?
|
| ADP-ribosyl Cyclase | 2 | 2000 | 33 | 0.090 |
Why?
|
| Leptin | 4 | 2013 | 307 | 0.090 |
Why?
|
| Cyclins | 3 | 2006 | 466 | 0.090 |
Why?
|
| DNA Primers | 3 | 2012 | 1421 | 0.090 |
Why?
|
| Diet | 2 | 2024 | 1476 | 0.090 |
Why?
|
| Fatigue | 3 | 2022 | 1265 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2010 | 198 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 4849 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 3106 | 0.080 |
Why?
|
| CD3 Complex | 2 | 2023 | 316 | 0.080 |
Why?
|
| United States | 3 | 2024 | 16312 | 0.080 |
Why?
|
| Myeloid Cells | 2 | 2023 | 276 | 0.080 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 638 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 569 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 230 | 0.080 |
Why?
|
| Mitosis | 2 | 2008 | 623 | 0.080 |
Why?
|
| Proteolysis | 2 | 2021 | 375 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2006 | 203 | 0.080 |
Why?
|
| Metformin | 4 | 2016 | 390 | 0.080 |
Why?
|
| STAT Transcription Factors | 2 | 2023 | 81 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2011 | 2361 | 0.080 |
Why?
|
| AraC Transcription Factor | 1 | 2008 | 6 | 0.080 |
Why?
|
| Oxides | 2 | 2021 | 210 | 0.080 |
Why?
|
| Europe | 2 | 2021 | 668 | 0.080 |
Why?
|
| Caspase 9 | 3 | 2010 | 189 | 0.080 |
Why?
|
| Transfection | 3 | 2014 | 2988 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 88 | 0.080 |
Why?
|
| Aerobiosis | 2 | 2021 | 30 | 0.080 |
Why?
|
| Sarcoma | 1 | 2019 | 1830 | 0.080 |
Why?
|
| Drug Substitution | 2 | 2018 | 87 | 0.080 |
Why?
|
| Disease Progression | 4 | 2021 | 6890 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 268 | 0.080 |
Why?
|
| Cell Nucleus | 4 | 2007 | 1644 | 0.080 |
Why?
|
| Platelet Count | 2 | 2019 | 494 | 0.080 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2007 | 22 | 0.080 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 489 | 0.070 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2007 | 40 | 0.070 |
Why?
|
| DNA, Neoplasm | 4 | 2018 | 1929 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 2520 | 0.070 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 453 | 0.070 |
Why?
|
| Mutation, Missense | 3 | 2019 | 1211 | 0.070 |
Why?
|
| Chromosome Deletion | 2 | 2022 | 1018 | 0.070 |
Why?
|
| Lysine | 2 | 2021 | 428 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 286 | 0.070 |
Why?
|
| Cyclin D | 1 | 2006 | 37 | 0.070 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2006 | 27 | 0.070 |
Why?
|
| Regulatory-Associated Protein of mTOR | 1 | 2006 | 14 | 0.070 |
Why?
|
| Transcription Factor HES-1 | 1 | 2007 | 49 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2005 | 296 | 0.070 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2007 | 93 | 0.070 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2006 | 62 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2022 | 689 | 0.070 |
Why?
|
| Mice, Inbred CBA | 2 | 2017 | 78 | 0.070 |
Why?
|
| Granulocytes | 1 | 2007 | 226 | 0.070 |
Why?
|
| Receptors, Leptin | 3 | 2004 | 65 | 0.070 |
Why?
|
| Melphalan | 2 | 2020 | 839 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2014 | 1082 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 122 | 0.070 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 261 | 0.070 |
Why?
|
| Annexin A5 | 2 | 2006 | 75 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2007 | 197 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 35 | 0.070 |
Why?
|
| Pregnadienes | 1 | 2005 | 2 | 0.070 |
Why?
|
| Pregnenediones | 1 | 2005 | 4 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2015 | 2323 | 0.070 |
Why?
|
| Binding Sites | 3 | 2019 | 2208 | 0.070 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2005 | 8 | 0.070 |
Why?
|
| Comorbidity | 3 | 2022 | 2454 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 1090 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2339 | 0.070 |
Why?
|
| Cell Adhesion | 2 | 2014 | 1016 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1261 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 125 | 0.070 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 293 | 0.070 |
Why?
|
| DNA Fragmentation | 2 | 2005 | 199 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2007 | 880 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2006 | 107 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 143 | 0.060 |
Why?
|
| Thiazoles | 2 | 2021 | 730 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2020 | 1512 | 0.060 |
Why?
|
| Agar | 1 | 2004 | 26 | 0.060 |
Why?
|
| Flavoproteins | 1 | 2004 | 33 | 0.060 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2004 | 21 | 0.060 |
Why?
|
| Staurosporine | 3 | 2015 | 144 | 0.060 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 251 | 0.060 |
Why?
|
| Rituximab | 2 | 2021 | 1551 | 0.060 |
Why?
|
| Phosphatidylserines | 1 | 2004 | 70 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 210 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2008 | 285 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2019 | 741 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 95 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2024 | 40 | 0.060 |
Why?
|
| Histological Techniques | 2 | 2015 | 66 | 0.060 |
Why?
|
| ARNTL Transcription Factors | 1 | 2024 | 57 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 1656 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2021 | 592 | 0.060 |
Why?
|
| Sucrose | 1 | 2024 | 63 | 0.060 |
Why?
|
| Etoposide | 3 | 2017 | 886 | 0.060 |
Why?
|
| RNA, Neoplasm | 2 | 2006 | 797 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6179 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2004 | 573 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 55 | 0.060 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 505 | 0.060 |
Why?
|
| Metaphase | 1 | 2003 | 106 | 0.060 |
Why?
|
| Cyclin E | 1 | 2005 | 273 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 471 | 0.060 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 342 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2022 | 3480 | 0.060 |
Why?
|
| Computational Biology | 2 | 2020 | 1298 | 0.060 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2023 | 77 | 0.060 |
Why?
|
| G1 Phase | 3 | 2009 | 293 | 0.060 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 749 | 0.050 |
Why?
|
| Haplotypes | 2 | 2018 | 883 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 689 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 1058 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 623 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 621 | 0.050 |
Why?
|
| Sezary Syndrome | 1 | 2004 | 163 | 0.050 |
Why?
|
| New York City | 1 | 2022 | 78 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 77 | 0.050 |
Why?
|
| K562 Cells | 3 | 2008 | 340 | 0.050 |
Why?
|
| Insulin, Long-Acting | 2 | 2012 | 18 | 0.050 |
Why?
|
| Insulin Glargine | 2 | 2012 | 20 | 0.050 |
Why?
|
| Plasmids | 1 | 2004 | 843 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5238 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2018 | 769 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2023 | 161 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7959 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2018 | 665 | 0.050 |
Why?
|
| Income | 1 | 2023 | 235 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 97 | 0.050 |
Why?
|
| Oxazoles | 1 | 2022 | 63 | 0.050 |
Why?
|
| Nausea | 2 | 2015 | 535 | 0.050 |
Why?
|
| North America | 1 | 2023 | 341 | 0.050 |
Why?
|
| Estradiol | 1 | 2005 | 761 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 61 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2022 | 1260 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 184 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1625 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 2942 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 240 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2022 | 1197 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 590 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2023 | 321 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 345 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 3234 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2022 | 85 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 92 | 0.050 |
Why?
|
| Minority Groups | 1 | 2024 | 328 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 4073 | 0.050 |
Why?
|
| Splicing Factor U2AF | 1 | 2021 | 48 | 0.050 |
Why?
|
| Lentivirus | 2 | 2015 | 171 | 0.050 |
Why?
|
| Community Health Services | 1 | 2022 | 131 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2014 | 92 | 0.050 |
Why?
|
| Gender Identity | 1 | 2021 | 81 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2021 | 88 | 0.050 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2021 | 94 | 0.050 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2020 | 18 | 0.050 |
Why?
|
| Calcium | 2 | 2006 | 1558 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 451 | 0.050 |
Why?
|
| Furans | 2 | 2014 | 106 | 0.050 |
Why?
|
| Karyotyping | 2 | 2017 | 1022 | 0.050 |
Why?
|
| Mycosis Fungoides | 1 | 2004 | 330 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2022 | 212 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 267 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 2214 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 104 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5531 | 0.050 |
Why?
|
| Urate Oxidase | 1 | 2020 | 35 | 0.050 |
Why?
|
| Epoxy Compounds | 2 | 2011 | 56 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 221 | 0.050 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2020 | 56 | 0.050 |
Why?
|
| Phosphorus | 1 | 2020 | 67 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2021 | 283 | 0.050 |
Why?
|
| Leukocytosis | 1 | 2020 | 114 | 0.050 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2020 | 103 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 133 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 1372 | 0.050 |
Why?
|
| Doxycycline | 1 | 2021 | 185 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 146 | 0.040 |
Why?
|
| Uric Acid | 1 | 2020 | 116 | 0.040 |
Why?
|
| Leukopenia | 1 | 2020 | 149 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 465 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 1263 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 278 | 0.040 |
Why?
|
| Graft Survival | 1 | 2004 | 1094 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 117 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 196 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 428 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 461 | 0.040 |
Why?
|
| Time | 1 | 2020 | 183 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 1508 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2020 | 184 | 0.040 |
Why?
|
| Immunotoxins | 1 | 2000 | 117 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 707 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2015 | 434 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 428 | 0.040 |
Why?
|
| Gene Duplication | 2 | 2014 | 433 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 905 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 25 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cell Tracking | 1 | 2019 | 38 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2020 | 334 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2008 | 531 | 0.040 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 1999 | 39 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 96 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2021 | 579 | 0.040 |
Why?
|
| Histone Deacetylases | 2 | 2015 | 365 | 0.040 |
Why?
|
| Dyspnea | 1 | 2022 | 425 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 83 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2021 | 633 | 0.040 |
Why?
|
| Diploidy | 1 | 2018 | 112 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 250 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 1458 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1417 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 153 | 0.040 |
Why?
|
| Inflammation | 2 | 2023 | 2570 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6457 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 128 | 0.040 |
Why?
|
| Liposomes | 1 | 2000 | 690 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2018 | 62 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 418 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2019 | 230 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 336 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2122 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 998 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 396 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 251 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2019 | 255 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2019 | 140 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 164 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 292 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 1007 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2017 | 1472 | 0.040 |
Why?
|
| Salmonella typhimurium | 1 | 2017 | 70 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 318 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2018 | 314 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 353 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Naphthyridines | 1 | 2017 | 42 | 0.040 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 210 | 0.040 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 706 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 1589 | 0.040 |
Why?
|
| Genome, Human | 2 | 2017 | 1896 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 259 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2017 | 54 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 471 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2017 | 219 | 0.040 |
Why?
|
| MEF2 Transcription Factors | 1 | 2016 | 49 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2017 | 87 | 0.040 |
Why?
|
| Phenformin | 1 | 2016 | 7 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 414 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 854 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 169 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 1429 | 0.040 |
Why?
|
| Rotenone | 1 | 2016 | 35 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2021 | 1768 | 0.030 |
Why?
|
| Cell Count | 1 | 2017 | 512 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 628 | 0.030 |
Why?
|
| Mitochondrial Proteins | 2 | 2009 | 380 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2019 | 358 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 86 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 350 | 0.030 |
Why?
|
| Protons | 1 | 2019 | 476 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2017 | 260 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 147 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 815 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2016 | 86 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 867 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 264 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 1129 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 125 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 154 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 360 | 0.030 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 265 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 342 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 80 | 0.030 |
Why?
|
| Karyopherins | 1 | 2017 | 135 | 0.030 |
Why?
|
| Telemedicine | 1 | 2022 | 529 | 0.030 |
Why?
|
| Cardiolipins | 2 | 2006 | 34 | 0.030 |
Why?
|
| Oncogenes | 1 | 2019 | 677 | 0.030 |
Why?
|
| Azure Stains | 1 | 2015 | 11 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 198 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 119 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 488 | 0.030 |
Why?
|
| Systems Integration | 1 | 2015 | 77 | 0.030 |
Why?
|
| Poly I-C | 1 | 2015 | 30 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 745 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 513 | 0.030 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2007 | 117 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 523 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 200 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 245 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 383 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 13879 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 256 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 841 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 611 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 1410 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1807 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 6122 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2015 | 206 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1852 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 69 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 947 | 0.030 |
Why?
|
| Propylene Glycols | 1 | 2014 | 38 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 2656 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 717 | 0.030 |
Why?
|
| Sphingosine | 1 | 2014 | 59 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 654 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2016 | 600 | 0.030 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 2014 | 97 | 0.030 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2014 | 50 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 372 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 745 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 83 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 851 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 698 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 88 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 135 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2013 | 50 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 597 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 328 | 0.030 |
Why?
|
| YY1 Transcription Factor | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 397 | 0.030 |
Why?
|
| Gene Editing | 1 | 2016 | 228 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2013 | 81 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1082 | 0.030 |
Why?
|
| Flavonoids | 2 | 2007 | 199 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 668 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 487 | 0.030 |
Why?
|
| Benzopyrans | 2 | 2004 | 41 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 307 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 353 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2005 | 652 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2014 | 190 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 2207 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 631 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1405 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 620 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 283 | 0.030 |
Why?
|
| Insulin Aspart | 1 | 2012 | 6 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2601 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2014 | 559 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 425 | 0.030 |
Why?
|
| Stents | 1 | 2019 | 1152 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 1158 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 2 | 2004 | 24 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 47 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 290 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 500 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2012 | 100 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 525 | 0.030 |
Why?
|
| C-Peptide | 1 | 2012 | 116 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 60 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 422 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 35 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 484 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 598 | 0.020 |
Why?
|
| Internet | 1 | 2016 | 728 | 0.020 |
Why?
|
| Replication Protein C | 1 | 2001 | 19 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 799 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 268 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1025 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 220 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3397 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 50 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 702 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 387 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 777 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2001 | 112 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 102 | 0.020 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2010 | 56 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2014 | 605 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2049 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 7903 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2014 | 763 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2010 | 160 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 265 | 0.020 |
Why?
|
| Uncoupling Protein 2 | 1 | 2009 | 27 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1222 | 0.020 |
Why?
|
| Fatty Acid Synthases | 1 | 2009 | 26 | 0.020 |
Why?
|
| beta Catenin | 1 | 2014 | 697 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 261 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2010 | 112 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 93 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 861 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3517 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 4277 | 0.020 |
Why?
|
| Bleomycin | 1 | 2001 | 478 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1534 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 692 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 183 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2017 | 968 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 5936 | 0.020 |
Why?
|
| Ion Channels | 1 | 2009 | 226 | 0.020 |
Why?
|
| Transgenes | 1 | 2010 | 569 | 0.020 |
Why?
|
| Research Design | 1 | 2016 | 1596 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4702 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2008 | 194 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4730 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 621 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 510 | 0.020 |
Why?
|
| Nicotinic Acids | 1 | 2007 | 35 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Luciferases, Renilla | 1 | 2007 | 10 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2007 | 95 | 0.020 |
Why?
|
| Fenretinide | 1 | 2007 | 98 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2012 | 1266 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 7733 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 715 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 889 | 0.020 |
Why?
|
| Filgrastim | 1 | 2007 | 191 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2007 | 94 | 0.020 |
Why?
|
| Response Elements | 1 | 2007 | 197 | 0.020 |
Why?
|
| Mitochondria, Liver | 1 | 2007 | 52 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1129 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 96 | 0.020 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 19 | 0.020 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2006 | 7 | 0.020 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2006 | 40 | 0.020 |
Why?
|
| G2 Phase | 1 | 2006 | 213 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2006 | 39 | 0.020 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 20 | 0.020 |
Why?
|
| Isomerism | 1 | 2005 | 63 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2007 | 147 | 0.020 |
Why?
|
| S Phase | 1 | 2006 | 285 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2007 | 284 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 107 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 42 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2006 | 236 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8546 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2005 | 70 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 1079 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2010 | 774 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2005 | 187 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 320 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 614 | 0.020 |
Why?
|
| Calcimycin | 1 | 2004 | 48 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4457 | 0.020 |
Why?
|
| Ionophores | 1 | 2004 | 24 | 0.020 |
Why?
|
| Spleen | 1 | 2007 | 692 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2004 | 118 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 369 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 200 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 493 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 802 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2007 | 913 | 0.010 |
Why?
|
| Progesterone | 1 | 2005 | 528 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 1323 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2010 | 1632 | 0.010 |
Why?
|
| Antibodies | 1 | 2006 | 842 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 217 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 323 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 522 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 366 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 1978 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2116 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2007 | 1716 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 1888 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 246 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 1506 | 0.010 |
Why?
|
| Biopsy | 1 | 2008 | 3486 | 0.010 |
Why?
|
| Phosphoserine | 1 | 1999 | 109 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 2387 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 881 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2004 | 1237 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 710 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 3097 | 0.010 |
Why?
|
| Testosterone | 1 | 2003 | 630 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 6204 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3693 | 0.010 |
Why?
|
| Melanoma | 1 | 2012 | 5444 | 0.010 |
Why?
|